Research Interests - R&D Projects

Bioszimiláris monoklonális antitestek fejlesztése

A „Versenyképességi és Kiválósági Szerződések” pályázaton támogatást nyert „Bioszimiláris monoklonális antitestek fejlesztése” című projekt (azonosító szám: VKSZ_12-1-2013-0001) megvalósításában a Richter Gedeon Nyrt. konzorciumvezető mellett az Eötvös Loránd Tudományegyetem, a Magyar Tudományos Akadémia Természettudományi Kutatóközpont  és a Debreceni Egyetem vesznek részt.​

 

​A konzorcium célja: korszerű eljárások és alapanyagok felhasználásával az eredetihez nagymértékben hasonlító gyógyszermolekulák előállítása a hatóságok által előírt klinikai vizsgálatokhoz. Az új, költséghatékony technológia kifejlesztésével a betegek a korszerű gyógyszerekhez alacsonyabb áron juthatnak majd hozzá.

A projekt megvalósításának időszaka: 2014.01.01.-2017.12.31.

A projekttel kapcsolatban további információ itt található.


 Micro RNA measuring with UPL based technique


 SCHIZO Biobank project

The aim of the project

The aim of the project is to develop biomarkers and methods to support, rationalize and accelerate the discovery and development of novel drugs for the treatment of psychotic disorders. As a result more effective drugs with fewer side effects than the existing ones can be put on the market.

The project consists of three tasks with the following goals:

  1. To establish a disease based biobank (named SCHIZOBANK) collecting both phenotypical and environmental data and biological materials from schizophrenic patients. It will be applied for the identification of genes and genetic variations that influence disease susceptibility. In addition it will be also used to find biomarkers, which speed up the diagnosis of the disease and help monitor the drugs' effect.
  2. The aim of this task is to reveal different relations between the symptoms and the treatment of schizophrenia at the molecular level by using the arsenal of the systems biology approach. We will identify biological and clinical predictors (biomarkers) of patient response and adverse side-effect profile during antipsychotic drug treatment.
  3. In this task we will determine markers and pathways of the metabolic syndrome adverse effect of antipsychotic in humans, in rodent experimental model systems, as well as in vitro cellular systems. The effect of prototypic antipsychotic drugs will be examined in these models and signatures of drug effects as well as mechanisms of action will be identified.

Members of the consortium

  1. UD-GenoMed Medical Genomic Technologies Research and Development and Service providing Ltd.
  2. Richter Gedeon Chemical factory Plc.
  3. Kripto Research and Development Ltd.
  4. University of Debrecen
  5. Hungarian Clinical Neurogenetic Society

schizo

Sections of work

1. To establish schizophrenia biobank

2. To identify schizophrenia and treatment-related molecular markers

3.1. Metabolic syndrome of the psychiatric disorders patients with AAP treatment: identify marker

3.2.-3.6. Metabolic syndrome of the psychiatric disorders patients with AAP treatment: identify marker: molecular mechanism research

 

Results

The above-mentioned stages of the professional background of clinical sample collection (quality assurance, determination of methodologies), as well as the infrastructure is completed, and we started filling the biobank. The peripheral blood of schizophrenic patients transcripts, proteomics and metabolomics analysis is in progress, caused by antipsychotic drugs of the side markers of metabolic syndrome, defined rodent samples is also underway.

Update 12.2010: Based on annual report 2010, closer the halftime of project, the results are convincing. The background of clinical sample preparation and collection, the follow-up of sample collection, the creation and continuous upload of clinical database, and the quality assurance requirements are ready to go. The hardware and software infrastructure of biobank have been set up, and connect to international biobank databases. Sample collection of patients processes according to plan, more than 300 samples are already collected by assign clinics. In the point of our success we look forward positively in the future and ready to work on the year 2011!

Contact

Gábor Zahuczky
Chief executive officer


Epigenetic kit development

The aim of the project

epigen

Our aim is to develop the prototype of kits adaptable in tumour genetics. The developed kits give the opportunity of introducing the investigations of chromatin (material of chromosomes) or epigenetic measurements to everyday routine.

In the past decade the discovery of differences in the chromatin (by epigenetic methods) transformed the definition of cancer diseases. This breakthrough was due to the technological development in the field of basic research. Although epigenetic techniques have greatly simplified, they are still not capable to be introduced into daily routine as clinical diagnostics. The main reason for this is the lack of adequate standards.

We are willing to produce kits to improve the reliability and sensitivity of epigenetic measurements enabling the utilization in routine clinical diagnostics.

Members of consortium

The leader of this in-process research is - besides our company - the Clinical Genomic Centre of Biochemistry and Molecular Biology Institute of University of Debrecen.

Results

Our R&D project of medical sciences and life sciences will generate a new market segment related to clinical diagnostics: the market of tumour diagnostics based on epigenetics (kits and methodology).

Project leader

Bálint László Bálint, M.D., Ph.D.
Head of laboratory


Biomarker identification and creating decision support system to increase effeciency of immune therapy in allergy.

The aim of the project of Csertex Ltd. and University of Debrecen is to identify biomarkers that would allow selection of allergic patients for immune therapy. The result of the project will be a decision support system in order to increase efficiency of immune therapy in allergy.

Tasks:

  • Develop a database system
  • Sample collection, coordination
  • Monitoring patients
  • Gene expression, biomarker measurement
  • Develop decision support system

Members of Consortium

Csertex Ltd.
University of Debrecen Medical Health Science Center

Result

This project started at 1st January 2012.